Drug Combinations for Advanced Melanoma
Researchers find that when treating metastatic melanoma, timing is everything.
Progress Against Cancer
Researchers find that when treating metastatic melanoma, timing is everything.
Many women are being diagnosed with cervical cancer, despite the availability of tools to prevent and diagnose the disease. Black and Hispanic women and low-income and rural populations are especially vulnerable.
New therapies are being developed to attack a previously untreatable cancer mutation.
American Cancer Society reacts to Supreme Court decision, and more from the week in cancer news.
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the second-line...
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) for pediatric patients 1 year of...
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the kinase...
Clinical trials rebound after COVID-19 setbacks, and early treatment leads to significant reduction in anal cancer risk among people with HIV.
Factors associated with the imaging facility, rather than individual characteristics, may explain some of the differences the accuracy of mammograms across racial and ethnic groups.
A new AACR report tracks progress in addressing cancer health disparities and identifies work that still needs to be done.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More